Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Change in Receivables: 2021-2025

Historic Change in Receivables for Keros Therapeutics (KROS) over the last 3 years, with Sep 2025 value amounting to -$12.3 million.

  • Keros Therapeutics' Change in Receivables fell 3309.38% to -$12.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 million, marking a year-over-year increase of 700.00%. This contributed to the annual value of $2.6 million for FY2024, which is 1717.48% up from last year.
  • Latest data reveals that Keros Therapeutics reported Change in Receivables of -$12.3 million as of Q3 2025, which was down 735.53% from -$1.5 million recorded in Q2 2025.
  • Over the past 5 years, Keros Therapeutics' Change in Receivables peaked at $18.0 million during Q4 2021, and registered a low of -$18.0 million during Q1 2022.
  • Over the past 3 years, Keros Therapeutics' median Change in Receivables value was $113,000 (recorded in 2023), while the average stood at $436,500.
  • The largest annual percentage gain for Keros Therapeutics' Change in Receivables in the last 5 years was 17,428.92% (2025), contrasted with its biggest fall of 3,309.38% (2025).
  • Over the past 5 years, Keros Therapeutics' Change in Receivables (Quarterly) stood at $18.0 million in 2021, then reached -$18.0 million in 2022, then reached $143,000 in 2023, then soared by 1,546.15% to $2.4 million in 2024, then plummeted by 3,309.38% to -$12.3 million in 2025.
  • Its Change in Receivables stands at -$12.3 million for Q3 2025, versus -$1.5 million for Q2 2025 and $14.5 million for Q1 2025.